Journal articleBMC Cancer2025
Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy for advanced pancreatic cancer.
- Journal
- BMC Cancer
- Published
- 12 March 2025
- Citations
- 1
- Type
- Article
- License
- cc by-nc-nd
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try